GAVRETO is a kinase inhibitor indicated for treatment of:...Adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer as detected by an FDA approved test (NSCLC).

...here we present interim data on the efficacy and safety of pralsetinib in prospectively identified patients with diverse RET fusion–positive tumors....Confirmed tumor responses were observed in all four patients with pancreatic cancer (including one CR), two of three patients with cholangiocarcinoma, two of three patients with sarcoma (including one CR), two of three patients with neuroendocrine cancer and single patients with head and neck cancer and unknown primary tumor (CR).

 Here we provide an update on the clinical activity of pralsetinib in patients (pts) with advanced RET fusion-positive solid tumors other than NSCLC and thyroid cancer (“other”RET fusion–positive solid tumors)….2/3 pts with cholangiocarcinoma, and in pts with mesenchymal, salivary duct, and lung carcinoid tumors.

Here, we present data on the clinical activity of pralsetinib in patients with RET fusion–positive solid tumor types....ORR (investigator’s assessment) was 50% (6/12; 95% CI: 21/79) and responses were observed in all patients with pancreatic cancer (3/3) and cholangiocarcinoma (2/2).

Activity of pralsetinib in various RET fusion-positive tumors… Responses were observed in all patients with pancreatic adenocarcinoma (3/3) and cholangiocarcinoma (2/2)